BeOne Medicines (ONC) Receivables - Net (2017 - 2026)
BeOne Medicines (ONC) posted quarterly Receivables - Net of $938.0 million for Q1 2026, up 30.78% year-over-year from $717.2 million in Q1 2025, and up 8.43% quarter-over-quarter from $865.1 million in Q4 2025.
BeOne Medicines (ONC) Receivables - Net (2017 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Receivables - Net for 10 consecutive years, with $938.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net rose 30.78% year-over-year to $938.0 million; the TTM figure through Mar 2026 stood at $938.0 million (up 30.78% YoY), while the FY2025 annual figure was $865.1 million, up 27.92% from the prior year.
- Receivables - Net advanced to $938.0 million in Q1 2026 per ONC's latest filing, from $865.1 million in the prior quarter.
- Across five years, Receivables - Net topped out at $938.0 million in Q1 2026 and bottomed at $172.3 million in Q2 2022.
- Historically, Receivables - Net has averaged $492.1 million across 5 years, with a median of $435.3 million in 2024.
- On a YoY basis, Receivables - Net climbed as much as 133.45% in 2022 and fell as far as 64.16% in 2022.
- BeOne Medicines' Receivables - Net stood at $173.2 million in 2022, then jumped by 106.75% to $358.0 million in 2023, then soared by 88.89% to $676.3 million in 2024, then grew by 27.92% to $865.1 million in 2025, then advanced by 8.43% to $938.0 million in 2026.
- Business Quant data shows ONC's Receivables - Net at $938.0 million in Q1 2026, $865.1 million in Q4 2025, and $863.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.06 Bn |
| Jun 30, 2026 | 1.06 Bn |
| Mar 31, 2026 | 938.02 Mn |
| Mar 31, 2026 | 938.02 Mn |
| Dec 31, 2025 | 865.08 Mn |
| Dec 31, 2025 | 865.08 Mn |
| Sep 30, 2025 | 863.28 Mn |
| Sep 30, 2025 | 863.28 Mn |
| Jun 30, 2025 | 770.78 Mn |
| Jun 30, 2025 | 770.78 Mn |
| Mar 31, 2025 | 717.24 Mn |
| Mar 31, 2025 | 717.24 Mn |
| Dec 31, 2024 | 676.28 Mn |
| Dec 31, 2024 | 676.28 Mn |
| Sep 30, 2024 | 569.05 Mn |
| Sep 30, 2024 | 569.05 Mn |
| Jun 30, 2024 | 529.45 Mn |
| Jun 30, 2024 | 529.45 Mn |
| Mar 31, 2024 | 435.29 Mn |
| Mar 31, 2024 | 435.29 Mn |